Personalized dosing may boost lupus kidney treatment success
NCT ID NCT07493655
First seen Apr 03, 2026 · Last updated Apr 29, 2026 · Updated 3 times
Summary
This study looks at whether adjusting the dose of an immunosuppressant drug (mycophenolate mofetil) based on regular blood tests can help more people with lupus-related kidney disease achieve remission. About 100 adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other gets dose adjustments guided by drug levels. The goal is to see if personalized monitoring leads to better kidney health over one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Hospital of the Federal University of Maranhão
São Luís, Maranhão, 65020-070, Brazil
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.